MX2011006524A - Profarmacos de peptido de la superfamilia de glucagon basado en amida. - Google Patents

Profarmacos de peptido de la superfamilia de glucagon basado en amida.

Info

Publication number
MX2011006524A
MX2011006524A MX2011006524A MX2011006524A MX2011006524A MX 2011006524 A MX2011006524 A MX 2011006524A MX 2011006524 A MX2011006524 A MX 2011006524A MX 2011006524 A MX2011006524 A MX 2011006524A MX 2011006524 A MX2011006524 A MX 2011006524A
Authority
MX
Mexico
Prior art keywords
glucagon superfamily
amide based
superfamily peptide
peptide prodrugs
based glucagon
Prior art date
Application number
MX2011006524A
Other languages
English (en)
Inventor
Richard D Dimarchi
Binbin Kou
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of MX2011006524A publication Critical patent/MX2011006524A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan formulaciones de profármacos de péptidos de la superfamilia de glucagón en donde el péptido de la superfamilia de glucagón ha sido modificado por la unión de un dipéptido a la superfamilia de glucagón a través de una ligadura de unión amida. Los profármacos divulgados en el presente han prolongado las semividas y son convertidos a la forma activa en condiciones fisiológicas a través de una reacción no enzimática dirigida por inestabilidad química.
MX2011006524A 2008-12-19 2009-12-18 Profarmacos de peptido de la superfamilia de glucagon basado en amida. MX2011006524A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13921008P 2008-12-19 2008-12-19
US14427109P 2009-01-13 2009-01-13
US18755609P 2009-06-16 2009-06-16
PCT/US2009/068745 WO2010071807A1 (en) 2008-12-19 2009-12-18 Amide based glucagon superfamily peptide prodrugs

Publications (1)

Publication Number Publication Date
MX2011006524A true MX2011006524A (es) 2011-08-17

Family

ID=42269125

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006524A MX2011006524A (es) 2008-12-19 2009-12-18 Profarmacos de peptido de la superfamilia de glucagon basado en amida.

Country Status (17)

Country Link
US (1) US8969288B2 (es)
EP (2) EP2376097A4 (es)
JP (2) JP2012512903A (es)
KR (1) KR20110110174A (es)
CN (1) CN102325539A (es)
AR (1) AR074811A1 (es)
AU (1) AU2009327418A1 (es)
BR (1) BRPI0922969A2 (es)
CA (1) CA2747499A1 (es)
CL (1) CL2011001498A1 (es)
IL (1) IL213113A (es)
MX (1) MX2011006524A (es)
PE (1) PE20120332A1 (es)
RU (1) RU2550696C2 (es)
SG (1) SG172291A1 (es)
TW (1) TWI489992B (es)
WO (1) WO2010071807A1 (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572952T3 (es) 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
AU2008205229B2 (en) 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
WO2008101017A2 (en) 2007-02-15 2008-08-21 Indiana Unversity Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2214691B1 (en) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
WO2009058662A2 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
EP2676673B1 (en) 2008-06-17 2016-11-16 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2010011439A2 (en) * 2008-06-17 2010-01-28 Indiana University Research And Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
JP5753779B2 (ja) * 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
US20110237493A1 (en) * 2008-12-19 2011-09-29 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
PE20120332A1 (es) * 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
EP2376520B1 (en) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
PE20120914A1 (es) 2009-06-16 2012-08-22 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
IN2012DN06437A (es) 2010-01-27 2015-10-09 Univ Indiana Res & Tech Corp
EP2568993A4 (en) 2010-05-13 2014-02-19 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY
KR20130062931A (ko) 2010-05-13 2013-06-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 핵 호르몬 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
US8940860B2 (en) 2010-06-16 2015-01-27 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
RU2013102991A (ru) * 2010-06-24 2014-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Связанные с дипептидом лекарственные средства
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY AMIDE PEPTIDE PRODRUGS
JP5912112B2 (ja) 2010-06-24 2016-04-27 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ アミド系インスリンプロドラッグ
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
AU2011348202A1 (en) * 2010-12-22 2013-07-04 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides
KR102002783B1 (ko) * 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
PE20140765A1 (es) 2011-06-10 2014-06-14 Hanmi Science Co Ltd Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
ES2710356T3 (es) 2011-06-17 2019-04-24 Hanmi Science Co Ltd Conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
CA2839867A1 (en) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
US9156902B2 (en) * 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
EP2578599A1 (en) 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
EP2802598B1 (en) * 2012-01-12 2017-12-06 University Of Ulster Peptides and peptide derivatives based on xenin
ES2810153T3 (es) 2012-03-01 2021-03-08 Novo Nordisk As Profármacos de GLP-1
TR201808818T4 (tr) 2012-06-21 2018-07-23 Novo Nordisk As Gip reseptör aktivitesi sergileyen glukagon analogları.
WO2013192129A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
CA2886228A1 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PH12018501454A1 (en) * 2012-11-06 2020-02-17 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglubin fragment
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
KR20150096684A (ko) 2012-12-21 2015-08-25 사노피 엑센딘-4 유도체
AU2014241743B2 (en) 2013-03-14 2018-07-05 Indiana University Research And Technology Corporation Insulin-incretin conjugates
WO2014152460A2 (en) * 2013-03-15 2014-09-25 Indiana University Research And Technology Corporation Prodrugs with prolonged action
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
WO2015157508A1 (en) * 2014-04-09 2015-10-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with pth activity
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
JP6657230B2 (ja) 2014-09-24 2020-03-04 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション インクレチン−インスリンコンジュゲート
ES2947409T3 (es) 2014-09-24 2023-08-08 Univ Indiana Res & Tech Corp Profármacos de insulina a base de amida lipídica
WO2016065090A1 (en) 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
JP6344348B2 (ja) 2015-09-14 2018-06-20 株式会社デンソー バッファ制御装置、通信ノード、及び中継装置
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2017074798A2 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Long-acting co-agonists of the glucagon and glp-1 receptors
EP3430033A4 (en) * 2016-03-18 2019-11-20 Merck Sharp & Dohme Corp. CONJUGATES OF INSULIN-INCRETIN
EP3468569A4 (en) * 2016-06-09 2020-05-27 AmideBio LLC GLUCAGON ANALOGS AND METHODS OF USING THE SAME
CA3038292A1 (en) 2016-09-28 2018-04-05 Cohbar, Inc. Therapeutic mots-c related peptides
CN106986924A (zh) * 2017-03-23 2017-07-28 中国药科大学 胃泌酸调节素（oxm）类似物及其应用
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
US11590237B2 (en) 2017-05-18 2023-02-28 Merck Sharp & Dohme Llc Pharmaceutical formulation comprising incretin-insulin conjugates
RU2721282C2 (ru) * 2017-11-21 2020-05-18 Илья Владимирович Духовлинов Способ лечения рассеянного склероза (варианты)
JP2018090636A (ja) * 2018-03-15 2018-06-14 インペリアル・イノベイションズ・リミテッド 新規化合物及び摂食行動に対するそれらの効果
MX2021008979A (es) 2019-01-28 2021-11-12 Cohbar Inc Peptidos terapeuticos.
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
MX2023000303A (es) 2020-07-22 2023-02-09 Novo Nordisk As Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
MX2023004672A (es) 2020-11-06 2023-07-20 Novo Nordisk As Profármacos de péptido tipo glucagón humano 1 (glp-1) y usos de los mismos.
JP2024503242A (ja) * 2020-12-24 2024-01-25 ハンミ ファーマシューティカル カンパニー リミテッド 短腸症候群の予防又は治療のためのインスリン分泌ペプチドとｇｌｐ－２の併用療法
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
KR20230149258A (ko) * 2022-04-18 2023-10-26 한미약품 주식회사 장질환의 예방 또는 치료를 위한 GLP-2와, 인슐린 분비 펩타이드, TNFα 억제제, 또는 이 둘 모두의 병용 요법
TW202346324A (zh) 2022-05-10 2023-12-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740385A (en) * 1970-05-07 1973-06-19 M Ondetti N-terminal derivatives of secretin
US4275152A (en) 1977-02-03 1981-06-23 Eastman Kodak Company Hydrolysis of protein-bound cholesterol esters
DK119785D0 (da) 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
PT83613B (en) 1985-10-28 1988-11-21 Lilly Co Eli Process for the selective chemical removal of a protein amino-terminal residue
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4741897A (en) 1986-07-08 1988-05-03 Baxter Travenol Thyroxine analogs and reagents for thyroid hormone assays
EP0628570A1 (en) 1989-02-17 1994-12-14 Chiron Mimotopes Pty. Ltd. Method for the use and synthesis of peptides
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
CA2024855C (en) 1990-09-07 1997-12-09 Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee Process and intermediates for producing glucagon
JPH04145099A (ja) 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途
US5510459A (en) 1991-01-17 1996-04-23 Zymogenetics, Inc. Glucagon antagonists
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5480867A (en) 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
DE69628909T2 (de) 1995-10-12 2003-12-24 Supergen, Inc. Liposomformulierung von 5-beta steroiden
US6180767B1 (en) 1996-01-11 2001-01-30 Thomas Jefferson University Peptide nucleic acid conjugates
WO1997029180A1 (en) 1996-02-06 1997-08-14 Eli Lilly And Company Diabetes therapy
CN1183158C (zh) 1996-06-05 2005-01-05 罗赫诊断器材股份有限公司 Exendin类似物,其制备方法及含有它们的药物制剂
CA2265454A1 (en) * 1996-09-09 1998-03-19 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998024464A1 (en) 1996-12-03 1998-06-11 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
WO2000020592A1 (en) 1998-10-07 2000-04-13 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
CZ295890B6 (cs) 1998-12-07 2005-11-16 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou pozici 8 a D-arginin na pozici 36, jejich použití a farmaceutické prostředky je obsahující
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
DE19908041A1 (de) 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
WO2000058360A2 (en) * 1999-03-29 2000-10-05 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
AUPQ661800A0 (en) 2000-03-31 2000-05-04 Metabolic Pharmaceuticals Limited Insulin-potentiating compounds
CA2405900A1 (en) 2000-04-27 2001-11-01 Bionebraska, Inc. Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
WO2001096368A2 (en) 2000-06-14 2001-12-20 Cytovax Biotechnologies, Inc. Use of coiled-coil structural scaffold to generate structure-specific peptides
DE60137876D1 (de) 2000-06-16 2009-04-16 Lilly Co Eli Analoge des Glucagon-ähnlichen Peptids-1
JP2004509079A (ja) 2000-08-02 2004-03-25 セラテクノロジーズ・インコーポレーテッド 効力が増大した修飾生体ペプチド
AU2001284697A1 (en) 2000-08-04 2002-02-18 Dmi Biosciences, Inc. Method of synthesizing diketopiperazines
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US20020045572A1 (en) 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
EP2295450B1 (en) 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegylated interleukin-10
US7199217B2 (en) 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
AU2002303431C1 (en) 2001-04-19 2008-03-06 The Regents Of The University Of California Methods and composition for the production of orthoganal tRNA-aminoacyltRNA synthetase pairs
US7576050B2 (en) 2001-07-31 2009-08-18 The United States Of America As Represented By The Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
EP1572885A2 (en) 2001-08-08 2005-09-14 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
US7238663B2 (en) 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
JP2005514337A (ja) 2001-10-18 2005-05-19 ブリストル−マイヤーズ　スクイブ　カンパニー ヒトグルカゴン様ペプチド−１模倣体、並びに糖尿病および関連疾患の処置におけるその使用
WO2003035099A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
SK2432004A3 (sk) 2001-12-20 2005-04-01 Eli Lilly And Company Inzulínová zlúčenina s protrahovaným účinkom
WO2003059378A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
CA2468700A1 (en) 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
EP1575490A4 (en) 2002-06-04 2007-08-08 Lilly Co Eli MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1)
AU2003237933A1 (en) 2002-06-11 2003-12-22 Cellartis Ab Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
WO2003105760A2 (en) 2002-06-15 2003-12-24 Enteromed, Inc. Prevention and treatment of nonalcoholic fatty liver disease (nafld) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (gip)
FR2842209B1 (fr) 2002-07-09 2007-11-23 Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique
CA2497794A1 (en) 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
WO2004078777A2 (en) 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
DK1605897T3 (da) 2003-03-19 2012-08-20 Lilly Co Eli Polyethelen-glycol-link-glp-1-forbindelser
SI1620118T1 (sl) 2003-04-08 2014-11-28 Yeda Research And Development Co., Ltd. Reverzibilna pegilirana zdravila
GB0310593D0 (en) 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
CN102174102A (zh) 2003-05-15 2011-09-07 塔夫茨大学信托人 肽和多肽药物的稳定类似物
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
PL1633390T3 (pl) 2003-06-03 2012-06-29 Novo Nordisk As Stabilizowane kompozycje farmaceutyczne peptydu glp-1
CN101974090B (zh) 2003-06-12 2015-06-17 伊莱利利公司 Glp-1类似物融合蛋白质
WO2004111078A2 (en) 2003-06-18 2004-12-23 Theratechnologies Inc. Compounds that modulate the glucagon response and uses thereof
WO2005025554A2 (en) 2003-09-09 2005-03-24 Japan Tobacco Inc. Dipeptidyl peptidase iv inhibitor
JP4949838B2 (ja) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
CN101380476A (zh) 2003-09-19 2009-03-11 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
WO2005035003A2 (en) 2003-09-22 2005-04-21 Dihedron Corporation Compositions and methods for increasing drug efficiency
US7364875B2 (en) 2003-10-30 2008-04-29 Cresent Innovations, Inc. Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
DE602004026113D1 (de) 2003-12-18 2010-04-29 Novo Nordisk As Glp-1-verbindungen
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20080318837A1 (en) 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
CN101035756A (zh) 2004-06-17 2007-09-12 南卡罗来纳州医科大学研究发展基金会 非天然氨基酸
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8404637B2 (en) 2005-02-11 2013-03-26 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
WO2006097536A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
WO2006121904A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
SI1881850T1 (sl) 2005-05-13 2011-01-31 Lilly Co Eli Glp-1 pegilirane spojine
EP2351776A1 (en) 2005-06-13 2011-08-03 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
CA2623412A1 (en) 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007028633A2 (en) 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
JP2009507847A (ja) 2005-09-08 2009-02-26 シャイア エルエルシー 生体利用性を増強したｔ３及びｔ４のプロドラッグ
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
ES2572952T3 (es) 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
US7928058B2 (en) 2006-02-22 2011-04-19 Merck Sharp & Dohme Corp. Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
ES2397659T3 (es) 2006-03-15 2013-03-08 Novo Nordisk A/S Mezclas de amilina e insulina
AU2007227202B2 (en) * 2006-03-21 2013-08-22 Amylin Pharmaceuticals, Llc Peptide-peptidase inhibitor conjugates and methods of using same
MX2008013304A (es) 2006-04-20 2008-10-27 Amgen Inc Compuestos de peptido 1 tipo glucagon.
WO2008022015A2 (en) 2006-08-11 2008-02-21 Trustees Of Tufts College Retro-inverso incretin analogues, and methods of use thereof
EP2057188B1 (en) * 2006-08-17 2013-07-31 Amylin Pharmaceuticals, LLC Dpp-iv resistant gip hybrid polypeptides with selectable properties
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
DE102006052755A1 (de) 2006-11-08 2008-05-15 N-Zyme Biotec Gmbh Michaelsysteme als Transglutaminaseinhibitoren
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
AU2008205229B2 (en) 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
WO2008101017A2 (en) * 2007-02-15 2008-08-21 Indiana Unversity Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
ATE520714T1 (de) 2007-06-15 2011-09-15 Zealand Pharma As Glucagonanaloga
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
EP2190873B1 (en) 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
EP2200626A4 (en) 2007-09-07 2012-02-15 Ipsen Pharma Sas ANALOGUE OF EXENDIN-4 AND EXENDIN-3
WO2009034117A1 (en) 2007-09-11 2009-03-19 Novo Nordisk A/S Mixture comprising an amylin peptide and a protracted insulin
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2214691B1 (en) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
WO2009058662A2 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
CN101918027A (zh) 2007-11-02 2010-12-15 森托科尔奥索生物科技公司 半合成GLP-1肽-Fc融合构造、方法及其用途
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
SI2237799T1 (sl) 2008-02-01 2019-07-31 Ascendis Pharma A/S Predzdravilo, ki obsega samo-cepljiv linker
WO2010011439A2 (en) 2008-06-17 2010-01-28 Indiana University Research And Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
EP2676673B1 (en) 2008-06-17 2016-11-16 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGATURE OF STAPLED POLYPEPTIDES
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
US20110237493A1 (en) 2008-12-19 2011-09-29 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
PE20120914A1 (es) 2009-06-16 2012-08-22 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AR079345A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
IN2012DN06437A (es) 2010-01-27 2015-10-09 Univ Indiana Res & Tech Corp
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
KR20130062931A (ko) 2010-05-13 2013-06-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 핵 호르몬 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
EP2568993A4 (en) 2010-05-13 2014-02-19 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY AMIDE PEPTIDE PRODRUGS
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers

Also Published As

Publication number Publication date
AR074811A1 (es) 2011-02-16
US20110288003A1 (en) 2011-11-24
RU2550696C2 (ru) 2015-05-10
EP3075385A1 (en) 2016-10-05
JP2012512903A (ja) 2012-06-07
IL213113A0 (en) 2011-07-31
CA2747499A1 (en) 2010-06-24
AU2009327418A1 (en) 2010-06-24
EP2376097A1 (en) 2011-10-19
RU2011129784A (ru) 2013-01-27
IL213113A (en) 2017-09-28
JP2015180649A (ja) 2015-10-15
CL2011001498A1 (es) 2012-03-09
TW201028162A (en) 2010-08-01
US8969288B2 (en) 2015-03-03
TWI489992B (zh) 2015-07-01
CN102325539A (zh) 2012-01-18
BRPI0922969A2 (pt) 2019-09-24
EP2376097A4 (en) 2012-10-03
PE20120332A1 (es) 2012-04-14
WO2010071807A1 (en) 2010-06-24
KR20110110174A (ko) 2011-10-06
SG172291A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
MX2011006524A (es) Profarmacos de peptido de la superfamilia de glucagon basado en amida.
WO2011163012A3 (en) Amide based glucagon superfamily peptide prodrugs
EP2585102A4 (en) AMID BASED INSULIN RPODRUGS
CL2004001602A1 (es) Compuestos no esteroidales derivados de propionanilida, moduladores del receptor androgenico con selectividad tisular (sarm); composicion farmaceutica; y uso en el tratamiento o prevencion de condiciones dependientes del receptor androgenico, como hi
MX2010009851A (es) Oblea gingival.
CY1118601T1 (el) Αλκυλαμινο-υποκατεστημενες δικυανοπυριδινες και προφαρμακα τυπου εστερα αμινοξεος αυτων
TN2011000172A1 (en) Therapeutic antiviral peptides
MX2020004912A (es) Compuestos derivados de prostaciclinas, y el uso de los mismo para el tratamiento de la hipertension pulmonar.
CR20120018A (es) Profármacos que comprenden un conjugado de insulina-conector
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
MY152979A (en) Novel insulin derivatives having an extremely delayed time-action profile
EP1861490A4 (en) USE OF ARRAYS TO MODULATE NUTRIENT CAPTURE FUNCTIONS BY THE GASTROINTESTINAL MICROBIOTE
MX2010004571A (es) Composiciones y metodos que comprenden peptidos y proteasas de aminoacidos basicos.
MX2012000973A (es) Compuestos para la reduccion de produccion de beta- amiloide.
SG10201809286XA (en) Biologically active peptides
MX2009010922A (es) Uso de poliamida como un material encapsulante para modulos fotovoltaicos.
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
EA201170703A1 (ru) Производные адамантилбензамида
FR2943538B1 (fr) Formulation a action rapide d'insuline recombinante humaine
MY156518A (en) Borinic compositions
IL190551A0 (en) Novel process for the preparation of acid chlorides
NZ706052A (en) Romidepsin solid forms and uses thereof
NZ733366A (en) Purification of iduronate-2-sulfatase
ATE427117T1 (de) Verwendung nativer peptide und deren optimierter derivate zur impfung
CY1117893T1 (el) Θεραπευτικα σχηματα

Legal Events

Date Code Title Description
FG Grant or registration